Specialty Pharmacy
M&A Diligence Playbook
QoE validates the historical earnings. The Strategic Capacity diligence validates whether the substrate can keep producing them under new ownership. In specialty pharmacy, the two layers together close the gap that drives 8 in 10 post-close failures.
What QoE catches in specialty pharmacy deals, and what it misses
A standard QoE on a specialty pharmacy target will validate the historical EBITDA, normalize adjustments, surface revenue recognition concerns, and stress-test the working capital. What it does not surface (and is not designed to surface) is whether the operating substrate underneath those earnings can transfer to a new owner without destroying value.
The five operational concerns that drive Strategic Capacity in specialty pharmacy and are typically invisible to financial diligence:
- URAC / ACHC accreditation maintenance
- Limited-distribution drug (LDD) access agreements
- PBM contract dynamics and DIR fees
- 340B exposure where applicable
- Patient retention and adherence rates
The Strategic Prime Architecture Clarity 1 Analysis, as a diligence layer
Run alongside the QoE, the Clarity 1 Analysis™ produces:
- The Strategic Capacity Score (0–100). Scored against the Asset Class Standard. Anything below 70 (Hardened band) signals material substrate risk to integration.
- Growth Capacity and Value Capacity sub-scores. Growth Capacity reads predictable profits and sustainable growth. Value Capacity reads M&A transaction readiness.
- The Three Dimensions diagnostic. Predictable Profits, Predictable Sustainable Growth, Predictable Transferable Value, each scored against the 24 Growth-Driving Objectives.
- The Battle-Ready Index baseline. Six factors of organizational and human capital substrate, scored. The instrument every Prime Architecture engagement runs against and re-scores at 90, 180, and 365 days.
The Battle-Ready Index, applied to specialty pharmacy diligence
In this sector, the binding factor is typically Architecture:
Bench
Leadership depth and succession readiness without founder dependency.
Architecture · most exposed in this industry
Operating systems, governance, decision rights, financial reporting discipline.
Transferability
Knowledge, customer relationships, and IP owned by the business, not by individuals.
Tempo
Operating cadence, financial discipline, reporting rhythm.
Loyalty
Retention, culture, and succession stickiness through ownership change.
Endurance
Pressure-tested capacity to absorb ownership change and scale demand.
Sector-specific diligence flags
Regulatory. State boards of pharmacy, DEA, URAC / ACHC accreditation, FDA REMS.
Workforce. Pharmacists, technicians, and patient care coordinators.
Customer pattern. Patient base plus payer relationships plus pharma manufacturer LDD access.
Platform dynamics. Active. Active buyers include pe platforms, strategic pharmacy / pbm firms, family offices.
Running QoE and the Clarity 1 Analysis together on a specialty pharmacy target shortens the diligence cycle, protects valuation against post-LOI re-trade, and surfaces integration risk before resource commitment. The five-day delivery cycle makes it pre-LOI viable for the first time.
For lenders pricing credit against this category
Cash flow durability through cycles is a Strategic Capacity question, not a financial one. The Clarity 1 Analysis informs spread, covenant structure, and facility-size decisions for specialty pharmacy borrowers by quantifying the company-specific risk component that financial metrics alone cannot surface.